Login to Your Account

Fibrocaps Hits Ph III Endpoints, Medicines Acquires Profibrix

By Nuala Moran
Staff Writer

Wednesday, August 7, 2013
LONDON – Profibrix NV announced positive results in the Phase III trial of Fibrocaps in promoting blood clotting during surgery, triggering the company's acquisition under a pre-arranged deal in which The Medicines Co. has purchased all the outstanding equity for $90 million and will pay up to $140 million on U.S. and European regulatory and sales milestones.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription